NEA Group Amends Champions Oncology Stake
Ticker: CSBR · Form: SC 13D/A · Filed: May 6, 2024 · CIK: 771856
| Field | Detail |
|---|---|
| Company | Champions Oncology, INC. (CSBR) |
| Form Type | SC 13D/A |
| Filed Date | May 6, 2024 |
| Risk Level | medium |
| Pages | 11 |
| Reading Time | 14 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-change, amendment, filing
Related Tickers: CHOS
TL;DR
NEA group updated their Champions Oncology stake filing on 5/6/24. Watch for changes.
AI Summary
New Enterprise Associates 14, L.P. (NEA 14 GP, LTD, NEA PARTNERS 14, L.P.) and associated individuals (Anthony A. Florence, Jr., Forest Baskett, Mohamad Makhzoumi, Patrick J. Kerins, Scott D. Sandell) have filed an amendment to their Schedule 13D on May 6, 2024, regarding their beneficial ownership of Champions Oncology, Inc. The filing indicates a change in their holdings, though specific dollar amounts or percentage changes are not detailed in this excerpt.
Why It Matters
This filing signals a potential shift in the investment strategy or ownership structure of Champions Oncology, Inc. by a significant venture capital firm.
Risk Assessment
Risk Level: medium — Changes in beneficial ownership filings can indicate shifts in investor sentiment or strategic intentions, potentially impacting the stock price.
Key Players & Entities
- New Enterprise Associates 14, L.P. (company) — Filing entity
- NEA 14 GP, LTD (company) — Group member
- NEA PARTNERS 14, L.P. (company) — Group member
- Champions Oncology, Inc. (company) — Subject company
- Anthony A. Florence, Jr. (person) — Group member
- Forest Baskett (person) — Group member
- Mohamad Makhzoumi (person) — Group member
- Patrick J. Kerins (person) — Group member
- Scott D. Sandell (person) — Group member
FAQ
What is the filing date of this SC 13D/A amendment?
The filing date is May 6, 2024.
Who is the subject company of this filing?
The subject company is Champions Oncology, Inc.
Which entity is primarily filing this amendment?
New Enterprise Associates 14, L.P. is primarily filing this amendment.
What are the names of the individuals listed as group members?
The individuals listed as group members are Anthony A. Florence, Jr., Forest Baskett, Mohamad Makhzoumi, Patrick J. Kerins, and Scott D. Sandell.
What was the former name of Champions Oncology, Inc. prior to 2007?
Prior to 2007, Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc.
Filing Stats: 3,376 words · 14 min read · ~11 pages · Grade level 7.4 · Accepted 2024-05-06 19:46:06
Key Financial Figures
- $0.001 — Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securiti
Filing Documents
- nea14-champions_18831.htm (SC 13D/A) — 320KB
- 0001072613-24-000427.txt ( ) — 322KB
Source
Item 3. Source and Amount of Funds or Other Consideration . Not applicable.
Purpose
Item 4. Purpose of Transaction . Not applicable. Item 5. Interest in Securities of the Issuer . (a) NEA 14 is the record owner of the 1,713,720 shares of Common Stock (the “NEA 14 Shares”), which amount includes 151,220 shares of Common Stock issued upon exercise in full of the Warrant on March 6, 2020 and reflects the 1-for-12 reverse stock split of outstanding shares of Common Stock on August 11, 2015. As the sole general partner of NEA 14, NEA Partners 14 may be deemed to own beneficially the NEA 14 Shares. As the sole general partner of NEA Partners 14, NEA 14 LTD may be deemed to own beneficially the NEA 14 Shares. As members of NEA 14 LTD, each of the Directors may be deemed to own beneficially the NEA 14 Shares. As an individual member of the Executive Committee, which committee has been delegated certain approval rights with respect to dispositions of the NEA 14 Shares, Makhzoumi may also be deemed to own beneficially the NEA 14 Shares. Each Reporting Person disclaims beneficial The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person’s cover sheet. Such percentage was calculated based on the 13,593,767 shares reported by the Issuer to be outstanding as of March 8, 2024 in the Issuer’s Form 10-Q filed on March 15, 2024. (b) Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets (ii) shared power to vote or to direct the vote: See line 8 of cover sheets (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets (c) Except as set forth in Item 3 above, none of the Reporting Persons has effected any transaction in the Common S